Navigation Links
Science Fuels DNA Testing Controversy with Prejudicial Misquote
Date:4/3/2008

SEATTLE, April 3, 2008 /PRNewswire/ -- A policy comment in Science today quotes Genelex out of context:

"Some Web sites make explicit claims about the utility of CYP450 testing for particular drugs, such as the claim by Genelex that pharmacogenetic testing is "required to effectively prescribe Paxil" (http://www.healthanddna.com/professional/paxil.html).

The actual statement is:

Paxil (paroxetine) is metabolized through CYP2D6. Pharmacogenetic testing of this pathway serves as an anchor for the intense personalization required to effectively prescribe Paxil and other antidepressant medicines.

Facts and quotes:

-- "The cytochrome P-450 test represents a major advance in the ability

to provide the best care possible for depression."

http://www.mayoclinic.org/depression/cytochrome.html.

-- Hospitalized psychiatric patients who are poor metabolizers cost

$4,000 - $6,000 more in medical care compared to patients with an

average metabolizer genotype. Virtually, all antidepressants and

antipsychotic medicines are processed by enzymes with a high

incidence of poor metabolizers. Journal of Clinical

Psycopharmacology 20:246 2000.

-- Fifty-nine percent of drugs most commonly cited in ADR studies are

processed by enzymes with genes known to have poor metabolizer

variants. This is compared to 7% of a random selection of the top

selling drugs. (JAMA 286:2270 2001).

-- Multiple studies have found that people with CYP variants require

lower doses of the affected medications. Molecular Psychiatry

9:442-473, 2004.

-- "Putting what we know into practice would prevent more disease than

worshiping at the altar of randomized trials." John Concato, MD,

Yale University.

Genelex's Position:

-- Individuals have a right to learn their genotype and control who

accesses this confidential information.

-- Excessive regulation will impede the already slow adoption of DNA

testing in medication management.

-- There needs to be symmetry between the level of proof required for

technology adoption and the potential risk and cost benefit ratios.

-- A peer-developed rating system needs to be developed that describes

where a given test lies on the continuum of scientific knowledge

about the utility, acceptance and proof of that test as a tool for

informed decision-making.

Randomized trials are in progress that will add to our knowledge. In the meantime clinicians and patients who find this information useful should have access to it. Physicians don't prescribe without knowing the patient's age, sex, and medical history, and often CYP genetics are more important than all these factors combined.


'/>"/>
SOURCE Genelex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis New Headquarters
2. Caliper Life Sciences Appoints Peter F. McAree Senior Vice President and Chief Financial Officer
3. Project Mind Survey of Israeli Ph.D. Scientists Favors a New Standard of Creativity in Science
4. Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations
5. Bioscience Career Fair in North Carolina Expected to Attract Well Qualified Job Seekers
6. Bioscience Career Fair in San Francisco Projected to Break Job Seeker Attendance Records
7. IC Sciences Launches ICS Alliance to Advance Development and Adoption of Informatics Instruments for Next Generation Healthcare
8. ABR-Affinity BioReagents to Exhibit at the Society for Biomolecular Sciences in St. Louis, April 6 - 10, 2008
9. As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
10. Derma Sciences Reports Fourth Quarter Year-End Results for 2007
11. Cardiac Science Signs Letter of Intent With Misys Healthcare Systems to Connect With Their EMR Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):